Q-omics provides the consensus-scored SNORA74D profile across patient tissues and cancer cell-line models. SNORA74D expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA74D is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SNORA74D RNA expression shows 14,002 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, COAD, and LSCC as cancer lineages where SNORA74D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA74D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA74D survival associations across molecular data types. SNORA74D RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA74D RNA expression–survival associations across cancer types. High SNORA74D expression shows unfavorable associations in KICH, UVM, LIHC, COAD, LUAD and CHOL. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA74D RNA expression.
This table summarizes SNORA74D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA74D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA74D shows higher tumor expression in COAD, LUSC, STAD, PRAD, KIRP and BRCA. The COAD box plot shows higher SNORA74D RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with SNORA74D in patient tissues and cancer cell lines. In patient samples, SNORA74D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
